Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis A case series of 21 patients and review of the Literature

European Journal of Anaesthesiology

Volumn 31, Issue 12, 2014, Pages 715-721

  De Boer, Hans D ^a   Shields, Martin O ^b   Booij, Leo H D J ^c  

^a MARTINI HOSPITAL   (Netherlands)

^b Department of Anaesthesia Royal Victoria Hospital   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIDOSTIGMINE; ROCURONIUM; SUGAMMADEX; VECURONIUM; GAMMA CYCLODEXTRIN DERIVATIVE;

ADULT; AGED; ANESTHETIC RECOVERY; CASE STUDY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; LETTER; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; NEUROMUSCULAR MONITORING; PATIENT SATISFACTION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; VERY ELDERLY; VULNERABLE POPULATION; ADVERSE EFFECTS; CASE REPORT;

ADULT; AGED; AGED, 80 AND OVER; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMUSCULAR BLOCKADE;

EID: 84928161613     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0000000000000153     Document Type: Letter

References (40)

1. Hirsch NP. Neuromuscular junction in health and disease. Br J Anaesth 2007; 99:132-138.
2. Briggs ED, Kirsch JR. Anesthetic implications of neuromuscular disease. J Anesth 2003; 17:177-185.
3. Dillon FX. Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 2004; 24:83-94.
4. Rudzka-Nowak A, Piechota M. Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex. Arch Med Sci 2011; 7:361-364.
5. Tripathi M, Kaushik S, Dubey P. The effect of the use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. J Postgrad Med 2003; 49:311-315.
6. Arbous MS, Meursing AEE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005; 102:257-268.
7. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41:266-270.
8. Amao R, Zornow MH, Cowan RM, et al. Use of sugammadex in patients with a history of pulmonary disease. J Clin Anesth 2012; 24:289-297.
9. Dahl V, Pendeville PE, Hollmann MW, et al. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol 2009; 26:874-884.
10. Osserman KE, Jenkins G. Studies on myasthenia gravis. Review of a twenty-year experience in over 1200 patients. Mount Sinai J Med 1971; 38:497-537.
11. Mann R, Blobner M, Jelen-Esselborn S, et al. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients. Anesthesiology 2000; 93:346-350.
12. Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: The Stockholm revision. Acta Anaesthesiol Scand 2007; 51:789-808.
13. Nakamori E, Nitahara K, Sugi Y, et al. Reversal of rocuronium induced neuromuscular block with sugammadex in a patient with myasthenia gravis. Masui 2013; 62:972-974.
14. Sugawara A, Sasakawa T, Hasegawa N, et al. Administration of sugammadex to a patient with myasthenia gravis with fade of the train-off our ratio. Masui 2011; 60:1082-1085.
15. Kiss G, Lacour A, d'Hollander A. Fade of train-of-four ratio despite administration of more than 12 mg/kg sugammadex in a myasthenia gravis patient receiving rocuronium. Br J Anaesth 2013; 110:854-855.
16. Sungur Ulke Z, Yavru A, Camci E, et al. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand 2013; 57:745-748.
17. Takeda A, Kawamura M, Hamaya I, et al. Case of anesthesia for thoracoscopic thymectomy in a pediatric patient with myasthenia gravis: reversal of rocuronium-induced neuromuscular blockade with sugammadex. Masui 2012; 61:855-858.
18. Garcia V, Diemunsch P, Boet S. Use of rocuronium and sugammadex for caesarean delivery in a patient with myasthenia gravis. Int J Obstet Anesth 2012; 21:286-287.
19. Jakubiak J, Gaszyński T, Gaszyński W. Neuromuscular block reversal with sugammadex in a morbidly obese patient with myasthenia gravis. Anaesthesiol Intensive Ther 2012; 44:28-30.
20. Komasawa N, Noma H, Sugi T, et al. Effective reversal of muscle relaxation by rocuronium using sugammadex in a patient with myasthenia gravis undergoing laparoscopic cholecystectomy. Masui 2011; 60:476- 479.
21. Argiriadou H, Anastasiadis K, Thomaidou E, Vasilakos D. Reversal of neuromuscular blockade with sugammadex in an obese myasthenic patient undergoing thymectomy. J Anesth 2011; 25:316-317.
22. de Boer HD, van Egmond J, Driessen JJ, Booij LH. Sugammadex in patients with myasthenia gravis. Anaesthesia 2010; 65:653.
23. Petrun AM, Mekis D, Kamenik M. Successful use of rocuronium and sugammadex in a patient with myasthenia. Eur J Anaesthesiol 2010; 27:917-918.
24. de Boer HD, van Egmond J, Driessen JJ, Booij LH. A new approach to anesthesia management in myasthenia gravis: reversal of neuromuscular blockade by sugammadex. Rev Esp Anestesiol Reanim 2010; 57:181-184.
25. Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia 2010; 65:302-305.
26. Eisenkraft JB, Book WJ, Mann SM, et al. Resistance to succinylcholine in myasthenia gravis: A dose-response study. Anesthesiology 1988; 69:760-763.
27. Romero A, Joshi GP. Neuromuscular disease and anesthesia. Muscle Nerve 2013; 48:451-460.
28. Zahid I, Sharif S, Routledge T, Scarci M. Video-assisted thoracoscopic surgery or transsternal thymectomy in the treatment of myasthenia gravis? Interact Cardiovasc Thorac Surg 2011; 12:40-46.
29. Paterson IG, Hood JR, Russell SH, et al. Mivacurium in the myasthenic patient. Br J Anaesth 1994; 73:494-498.
30. Baraka A, Siddik S, Kawkabani N. Cisatracurium in a myasthenic patient undergoing thymectomy. Can J Anaesth 1999; 46:779-782.
31. Sanfilippo M, Fierro G, Cavalletti MV, et al. Rocuronium in two myasthenic patients undergoing thymectomy. Acta Anaesthesiol Scand 1997; 41:1365-1366.
32. Sungur Ulke Z, Senturk M. Mivacurium in patients with myasthenia gravis undergoing video-assisted thoracoscopic thymectomy. Br J Anaesth 2009; 103:310-311.
33. Seigne RD, Scott RP. Mivacurium chloride and myasthenia gravis. Br J Anaesth 1994; 72:468-469.
34. Osmer C, Vogele C, Zickmann B, Hempelmann G. Comparative use of muscle relaxants and their reversal in three European countries: A survey in France, Germany and Great Britain. Eur J Anaesthesiol 1996; 13:389- 399.
35. Osmer C, Vogele C, Zickmann B, Hempelmann G. Effects of four anticholinesterase-anticholinergic combinations and tracheal extubation on QTc interval of the ECG, heart rate and arterial pressure. Acta Anaesthesiol Scand 1998; 42:460-463.
36. Baurain MJ, Hoton F, D'Hollander AA, Cantraine FR. Is recovery of neuromuscular transmission complete after the use of neostigmine to antagonize block produced by rocuronium, vecuronium, atracurium and pancuronium? Br J Anaesth 1997; 77:496-499.
37. Heliopoulos I, Patlakas G, Vadikolias K, et al. Maximal voluntary ventilation in myasthenia gravis. Muscle Nerve 2003; 27:715-719.
38. Eikermann M, Zaremba S, Malhotra A, et al. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008; 101:344-349.
39. Plaud B, DeBaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology 2010; 112:1013-1022.
40. Eikermann M, Brueckmann B, Sasaki N, et al. The use of sugammadex eliminated postoperative residual neuromuscular blockade at postanaesthesia care unit admission in abdominal surgery: 9AP 1-5. Eur J Anaesth 2013; 30:140-141.